New Data. Certain Silverline SaaS Offerings allow you to receive data from us that we own or license from a third party, or that we create through proprietary analysis and modeling of Customer Data alone or in combination with other data, such as risk score, intelligence about a threat from some source other than Customer Data, or substantiation of either of the foregoing (collectively, “New Data”). New Data does not include Customer Data. As between you and us, we own and retain all rights, title and interest in and to the New Data, and you may use New Data only for your lawful, internal cybersecurity analysis/auditing purposes in accordance with this Agreement. You are responsible for proper security of any New Data you receive. Unless prohibited by law, you will promptly inform us of any request from a third party to exercise any purported rights with respect to the New Data.
New Data. Any New Data generated or developed jointly by the Members in accordance with this Agreement shall be owned jointly by the Members provided that the individual Members have contributed to the costs thereof in accordance with this Agreement. Each of the joint owners shall obtain a full copy of the New Data. Any New Data is Confidential Information and joint proprietary data and shall be treated as such under this Agreement. The New Data shall not for the period of 12 years from the date of initial submission to the Agency be sold, licensed or otherwise made available to third parties by any Member without prior written approval of 2/3 of the owners who have financially contributed to the costs thereof unless otherwise agreed by the Members, or required by law or in civil or criminal litigation, provided that the Member shall obtain approval of the Steering Committee for any submission and shall provide a copy of the court order.
New Data. Certain of the SaaS Offerings allow you to receive data from us that we own or license from a third party, or that we create through proprietary analysis and modeling of Threat Data and/or Customer Data alone or in combination with other data, such a risk score, intelligence about a threat from some source other than Customer Data, or substantiation of any of the foregoing (the “New Data”). New Data does not include Customer
New Data. Notwithstanding Sections 5.10, 5.11(a) and 5.12, in the event that GSK requires information relating to the Bulk Tablets in addition to that provided by or otherwise readily available to Sepracor to support GSK’s regulatory filings for Product in the GSK Territory, Sepracor shall conduct, at GSK’s expense, such work as is necessary to produce the necessary chemistry, manufacturing and controls (“CMC”) information or other regulatory documentation reasonably required to support such regulatory filings (provided that GSK shall be responsible for, at its expense, any additional clinical trial work required for such filings). The obligation of Sepracor to provide such CMC data or other regulatory documentation reasonably required to support such regulatory filings will include, without limitation, CMC information or other regulatory documentation reasonably required to support such regulatory filings beyond what was required for the U.S.A. regulatory approval, to support initial as well as filed regulatory submissions for Product in the GSK Territory, support on an ongoing basis to deal with regulatory questions, provision of on-going stability data, batch analysis, etc. for license renewals, CMC data for variations, any response to questions relating to renewals and variations, as well as any other data required to meet any regulatory inspection requirements. For the avoidance of doubt, Sepracor’s obligations do not extend to questions regarding finishing operations performed by GSK.
New Data. During the Term, the Licensee shall have the right from time to time to request to have included in the license granted under this Agreement those portions of any Databases that the Licensor owns, or of any Third Party Databases that the Licensor has, from time to time, the right to provide to the Licensee in the manner and for the purposes set out in, and as contemplated by, section 2.0, in each case which portions consist of the specific types of information set forth in Appendix I (the "NEW DATA") on the most favorable fee or royalty and other terms and conditions as the Licensor shall offer to customers of the DQI2 Database, or of the successors to such Database (taking into account economic and other material terms). If the Licensee exercises its right to have the New Data included in the license granted under this Agreement pursuant to this section 2.1, the parties shall promptly prepare and sign a modification to this Agreement or other document embodying the terms contemplated hereby with respect thereto. Upon the development of any New Data during the Term, Licensor shall provide Licensee with a written report describing such New Data. Licensor shall at all times have the right to use and offer to Third Parties licenses for the New Data except to those third parties listed in Exhibit 2.0 with respect to the Exclusive Permitted Applications (other than the one described at clause (iii) of that defined term, which, for the purposes of this section 2.1, shall not be deemed to be an Exclusive Permitted Application). Nothing in this section 2.1 shall prevent the Licensor from using or licensing the New Data for any purposes except, during the Term, the Exclusive Permitted Applications and, then, only to the extent provided in section 2.3.
New Data. (a) The Employer shall provide the Union with the following information within five calendar days of the starting date of a new employee: the employee’s name, address, department or branch at which employed, starting date and classification and salary level at which the employee started and in the case of a temporary or term employee, both the starting date and termination date. Upon request, and no more than every four months, the Employer shall furnish the Union with a list of the name and address of all Reserve time employees.